Relay Therapeutics Is A Buy For Its Superb Safety Data

Company Overview - Relay Therapeutics is focused on precision oncology, with its lead asset RLY-2608 being an allosteric and pan-mutant PI3Kα inhibitor targeting breast cancer [1] - RLY-2608 is currently in phase 3 trials after showing positive interim results [1] Investment Strategy - The company is part of a broader investment strategy that emphasizes building a resilient, income-generating portfolio with a long-term growth mindset [1] - The approach is primarily long-only, blending dividend-paying equities, REITs, and selective growth opportunities [1] - The investment philosophy prioritizes disciplined, fundamentals-driven investing, focusing on capital preservation while compounding returns over time [1]